The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

Reid-Nicholson, Michelle; Ramalingam, Preetha; Adeagbo, Bamidele; Cheng, Ningli; Peiper, Stephen C.; Terris, Martha K.

doi:10.1038/modpathol.2008.179

Cited by 35 publications

(23 citation statements)

References 29 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that fluorescently labeled probes of chromosomes 3, 7, 17 and 9 could detect bladder UC as a non-invasive and sensitive test [5,6,7,9,10,14,15,16,17,18,19,20,21,22]. To date, few groups reported their studies on the utility of FISH in the detection of UUT-UC [23,24,25].…”

Section: Discussionmentioning

confidence: 99%

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Wang

Wu²,

Peng³

et al. 2012

Acta Cytologica

View full text Add to dashboard Cite

Objective: The aims of this study were to evaluate the clinical utility of a fluorescence in situ hybridization (FISH) assay as a non-invasive molecular test to distinguish urothelial carcinoma (UC) in the upper urinary tract (UUT) from benign lesions presenting with hematuria. Study Design: The chromosomal abnormalities of chromosomes 3, 7, 17 and 9 (p16) in hematuria specimens from 34 patients with UUT-UC and 33 patients with benign disorders were detected using a set of fluorescently labeled DNA probes. The abnormalities of the chromosomes were determined and analyzed between UUT-UC and benign disorders. Results: Chromosomal abnormalities were detected in 25 of 34 (73.5%) patients with UUT-UC and in 2 of 33 (6.1%) patients with benign disorders (p < 0.001). Conclusions: FISH of chromosomes 3, 7, 9 and 17 performed on exfoliated cells from voided urine specimens may serve as a non-invasive tool to distinguish UUT-UC from benign disorders presenting with hematuria.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Wang

Wu²,

Peng³

et al. 2012

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…However, such chromosomal abnormalities observed using UroVysion were not restricted to urothelial carcinoma, for a significant possibility of false positive diagnosis [50]. In low-grade tumors, the sensitivity of UroVysion was 40.8%, while the specificity was 87.8% [22].…”

Section: Non-invasive Urine Markersmentioning

confidence: 99%

“…Other non-invasive urine-based bladder cancer tests have been developed in the last few years, such as UroVysion fluorescence in situ hybridization (FISH) [50] and CxBladder Detect [49]. The UroVysion kit is one of the key Food and Drug Administration (FDA) -approved non-invasive devices commonly used for bladder cancer detection in actual clinical settings.…”

Section: Non-invasive Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Microdevices for Non-Invasive Detection of Bladder Cancer

et al. 2017

View full text Add to dashboard Cite

Bladder cancer holds the record for the highest lifetime cost on a per-patient basis. This is due to high recurrence rates, which necessitate invasive and costly long-term evaluation methods such as cystoscopy and imaging. Microfluidics is emerging as an important approach to contribute to initial diagnosis and follow-up, by enabling the precise manipulation of biological samples. Specifically, microdevices have been used for the isolation of cells or genetic material from blood samples, sparking significant interest as a versatile platform for non-invasive bladder cancer detection with voided urine. In this review, we revisit the methods of bladder cancer detection and describe various types of markers currently used for evaluation. We detail cutting-edge technologies and evaluate their merits in the detection, screening, and diagnosis of bladder cancer. Advantages of microscale devices over standard methods of detection, as well as their limitations, are provided. We conclude with a discussion of criteria for guiding microdevice development that could deepen our understanding of prognoses at the level of individual patients and the underlying biology of bladder cancer development. Collectively, the development and widespread application of improved microfluidic devices for bladder cancer could drive treatment breakthroughs and establish widespread, tangible outcomes on patients' long-term survival.

show abstract

“…1). Moreover, when source of tumor cell is questionable (17,18), it is difficult to determine the true origin of a FISH positive nucleus. To eliminate human senses and avoid variety in subjective interpretation of targeting, we have recently developed a combined method (19).…”

mentioning

confidence: 99%

Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria

et al. 2011

View full text Add to dashboard Cite

Urovysion multitarget fluorescence in situ hybridization (FISH) assay is a promising tool for detection of bladder cancer, however, there is still no consensus regarding abnormal signal pattern and cut-off level, and the recommended targeting carries limitations similar to urine cytology. Aim of this study was to explore diagnostic benefits of a recently introduced method featuring target specific genotyping, as well as to investigate the feasibility of locally and statistically determined cut-off, compared with conventional evaluation scheme. Histology, cytology, and comparative FISH approaches were performed on 42 patients with high clinical suspicion for urothelial carcinoma (UC). FISH parallels were (1) Urovysion-alone (according to manufacturer's instruction); (2) Targeted-Urovysion (cytokeratin7 immunophenotyping followed by Urovysion), both of which evaluated by both conventional and statistical evaluation scheme. For statistical evaluation cut-offs and sufficient sample size were determined on controls and ratio of positive cells was recorded, whereas conventional evaluation relied on manufacturer's recommendations. The specificity of cytology, Urovysion-alone in general and targeted-Urovysion in general appeared 86%, 86%, and 100%, respectively. In the same comparison, overall sensitivity was 60%, 80%, and 93%, respectively. In superficial cases sensitivity was 48% for cytology, 72% for Urovysion-alone and 91% for targeted-Urovysion, while no prominent differences were seen in muscle invasive cases. The ratio of FISH positive cells was proportionate with both stage and grade, however, targeted genotyping could separate high grade/high stage cases more effectively. In conclusion, CK7 targeting raises diagnostic efficiency of Urovysion, and could be an ideal tool for identifying tumor cells in ambiguous cases or when other tumors are present. Statistical evaluation produces accuracy comparable with results of conventional evaluation, and with laboratories setting cut-offs individually but according harmonized protocol, it could aid method standardization. Furthermore, by providing additional quantitative information about tumor characteristics, is likely to have therapy relevant value in the future. ' 2011 International Society for Advancement of Cytometry Key terms bladder cancer; targeted FISH; diagnostic cut-off value; CK7 immunophenotyping; automation BLADDER cancer is the seventh most common cancer in women and fourth most common in men (1). Urothelial carcinoma (UC) is the most frequent form, standing as the second most common cause of death in urinary tract malignancies (1). After transurethral resection (TUR) recurrence rate is 30-70%, and the chance of progression at 5 years is 10-30% (2). Monitoring and thorough follow-up of patients is indispensable and early detection of high grade tumors could have a great prognostic

show abstract

The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

Cited by 35 publications

References 29 publications

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Microdevices for Non-Invasive Detection of Bladder Cancer

Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria

Contact Info

Product

Resources

About